Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects

BACKGROUND AND OBJECTIVE: Dabigatran etexilate (DE) is an anticoagulant with proven efficacy and tolerability for stroke prevention in patients with non-valvular atrial fibrillation. For the commercial capsule, a complex formulation is used to maintain the acidic microenvironment required for maxima...

Descripción completa

Detalles Bibliográficos
Autores principales: Harada, Akiko, Ikushima, Ippei, Haranaka, Miwa, Yanagihara, Aki, Nakayama, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266796/
https://www.ncbi.nlm.nih.gov/pubmed/31667735
http://dx.doi.org/10.1007/s40256-019-00377-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266796/
https://www.ncbi.nlm.nih.gov/pubmed/31667735
http://dx.doi.org/10.1007/s40256-019-00377-x

Ejemplares similares